Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility
- Author:
Sandra VILLANUEVA
1
;
Fernando GONZÁLEZ
;
Eduardo LORCA
;
Andrés TAPIA
;
G VALENTINA LÓPEZ
;
Rocío STRODTHOFF
;
Francisca FAJRE
;
Juan E CARREÑO
;
Ricardo VALJALO
;
César VERGARA
;
Manuel LECANDA
;
Jorge BARTOLUCCI
;
Fernando E FIGUEROA
;
Maroun KHOURY
Author Information
- Publication Type:Original Article
- Keywords: Adipose tissue-derived mesenchymal stromal cells; Chronic kidney disease; Mesenchymal stromal cell transplantation; Proteinuria; Stem cells
- MeSH: Disease Progression; Glomerular Filtration Rate; Humans; Infusions, Intravenous; Mesenchymal Stromal Cells; Pilot Projects; Proteinuria; Public Health; Renal Insufficiency, Chronic; Stem Cells
- From:Kidney Research and Clinical Practice 2019;38(2):176-185
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Chronic kidney disease (CKD) is a growing public health concern, and available treatments are insufficient in limiting disease progression. New strategies, including regenerative cell-based therapies, have emerged as therapeutic alternatives. Results from several groups, including our own, have reported evidence of a supportive role for mesenchymal stromal cells (MSCs) in functional recovery and prevention of tissue damage in murine models of CKD. Prompted by these data, an open pilot study was conducted to assess the safety and efficacy of a single injection of autologous adipose tissue-derived MSCs (AT-MSCs) for treatment of CKD. METHODS: AT-MSCs were infused intravenously into six CKD patients at a dose of 1 million cells/kg. Patients were stabilized and followed for one year prior to MSC infusion and one year following infusion. RESULTS: No patients presented with adverse effects. Statistically significant improvement in urinary protein excretion was observed in AT-MSCs transplanted patients, from a median of 0.75 g/day (range, 0.15–9.57) at baseline to 0.54 g/day (range, 0.01v2.66) at month 12 (P = 0.046). The glomerular filtration rate was not significantly decreased post-infusion of AT-MSCs. CONCLUSION: Findings from this pilot study demonstrate that intravenous infusion of autologous expanded AT-MSCs into CKD patients was not associated with adverse effects and could benefit patients already undergoing standard medical treatment.
